At BIO Asia–Taiwan 2025, Plenary Session 2 brought together global biotech leaders to explore the industry’s evolving landscape and the strategies driving scientific breakthroughs to market. Manuel Sanz, COO of Oncomatryx Biopharma, opened with insights on how collaborative “teamnovation” advanced OMTX705 from the lab to the clinic. David Flores, Co-Founder and CEO of BioCentury, followed … Next-Gen Biotech Innovation Driving Cancer Therapy Genomics, AI-Powered Trials, and APAC’s Global Rise at BIO Asia-Taiwan 2025 Read More » To access this post, you must purchase Individual Subscriber Yearly or Enterprise Subscriber.